These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 15832997)

  • 1. [Drug politics--economic view-point of a practitioner].
    Băicuş C; Chivu R
    Rev Med Chir Soc Med Nat Iasi; 2004; 108(3):674-8. PubMed ID: 15832997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of HMG coenzyme reductase inhibitors; whom to treat?
    van Hout BA; Simoons ML
    Eur Heart J; 2001 May; 22(9):751-61. PubMed ID: 11350107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Which statin is most efficient for the treatment of hypercholesterolemia? A cost-effectiveness analysis.
    Cobos A; Jovell AJ; García-Altés A; García-Closas R; Serra-Majem L
    Clin Ther; 1999 Nov; 21(11):1924-36. PubMed ID: 10890264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing the effect of Taiwan's outpatient prescription drug copayment policy in the elderly.
    Liu SZ; Romeis JC
    Med Care; 2003 Dec; 41(12):1331-42. PubMed ID: 14668666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
    Mullins CD; Rattinger GB; Kuznik A; Koren MJ
    Clin Ther; 2008; 30 Pt 2():2204-16. PubMed ID: 19281915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia.
    Hilleman DE; Phillips JO; Mohiuddin SM; Ryschon KL; Pedersen CA
    Clin Ther; 1999 Mar; 21(3):536-62. PubMed ID: 10321422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of drug expenditure in medical departments from tertiary hospitals.
    Duma O
    Rev Med Chir Soc Med Nat Iasi; 2004; 108(1):189-93. PubMed ID: 15688783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost-effectiveness of drug treatments for primary prevention of cardiovascular disease: a modelling study.
    Marshall T
    Eur J Cardiovasc Prev Rehabil; 2006 Aug; 13(4):523-8. PubMed ID: 16874140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statin's cost-effectiveness: a Canadian analysis of commonly prescribed generic and brand name statins.
    Tran YB; Frial T; Miller PS
    Can J Clin Pharmacol; 2007; 14(2):e205-14. PubMed ID: 17556788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug policy: the challenge is to overcome fragmentation.
    McFarlance A
    Healthc Pap; 2002; 3(1):38-42: discussion 87-94. PubMed ID: 12811109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY; Ko SK; Liew D
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pattern of statins' utilization at Ramathobodi Hospital, 2005 to 2007.
    Pattanaprateep O; Pongcharoensuk P; Suvanakoot P; Kaojarern S
    J Med Assoc Thai; 2010 Oct; 93(10):1223-31. PubMed ID: 20973328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic aspects of hypercholesterolemia treatment with HMG-CoA reductase inhibitors: a review of recent developments.
    MacNeil P
    Can J Cardiol; 1998 Apr; 14 Suppl A():14A-16A. PubMed ID: 9594928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of severe arterial hypertension: cost of drug prescriptions in accordance with ANAES guidelines].
    Fender P; Guilhot J; Tilly B; Salanave B; Allemand H
    Therapie; 2001; 56(2):111-8. PubMed ID: 11471361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dialogue. Prescription for problems? Capitating mental health drugs--the great debate.
    Docherty JP; Browne RA; Farmer M
    Behav Healthc Tomorrow; 1998 Oct; 7(5):32-8. PubMed ID: 10185199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of managerial intervention on drug utilization pattern at King Chulalongkorn Memorial Hospital.
    Limpanasithikul W; Wangsaturaka D; Nantawan P; Itthipanichapong C; Thamaree S; Wittayalertpanya S; Ketcharoen A; Taworn N; Kemsri W; Kusolsomboon T; Tangphao O
    J Med Assoc Thai; 2002 Jun; 85 Suppl 1():S336-43. PubMed ID: 12188432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of amount, expenditures and indications of drug and blood product prescriptions at surgical intensive care units.
    Tepper J; Schäfer R; Hoffmann A
    Int J Clin Pharmacol Ther; 1995 Dec; 33(12):658-63. PubMed ID: 8963483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Reimbursement prescription system in poor state?].
    Sundar T; Thuestad AB; Thomassen PT; Røshol H; Hjelme K; Andestad U; Bryn E
    Tidsskr Nor Laegeforen; 2006 Jun; 126(13):1759-61. PubMed ID: 16794672
    [No Abstract]   [Full Text] [Related]  

  • 19. Cost effectiveness of statin therapy for the primary prevention of coronary heart disease.
    Walshe V; Nash A; Barry M
    Ir Med J; 2006 May; 99(5):144-5. PubMed ID: 16892920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs.
    Berry SR; Bell CM; Ubel PA; Evans WK; Nadler E; Strevel EL; Neumann PJ
    J Clin Oncol; 2010 Sep; 28(27):4149-53. PubMed ID: 20697077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.